Dr. Clay Siegall: Transforming Lives Via Targeted Cancer Therapies

Cancer research is one of the most valuable and well-respected industries of all-time. Having the knowledge and the capabilities to fight this deadly disease can’t be put into words. There are numerous cancer research institutions around the globe, but one of the best is located right in the U.S. Seattle Genetics is its name and eradicating cancer is its game. CEO Clay Siegall has done an extraordinary job of leading this company to the top of the ranks. Siegall is one of the most knowledgeable individuals in this field of work, and he has been doing his part to better mankind.

Seattle Genetics, a biotech oncology company, specializes in the development and the commercialization of these advanced medications. The company was founded back in the late 1990s. It was basically a small startup company, but who knew that it would manifest into a worldwide powerhouse years later. Siegall has implemented the three main principles of success, which has helped to build its foundation. This includes drug development, scientific innovation and rigorous research. Even when things weren’t going as planned in the beginning, Clay  Siegall had to take a step back to restructure the company’s business plan. In other words, Siegall brought in a dynamic sales team that had expertise in biotech as well as business. After implementing this team into the fold, Seattle Genetics began to grow at an astounding rate. This team of experts were completing seven and eight-figure deals on a consistent basis.

Seattle Genetics is on another level thanks to its great leadership, its wonderful efficiency and its extraordinary products. ADCETRIS, the company’s top drug, is now being used all across the globe in more than 65 countries. ADCETRIS has also generated more than $350 million, which has helped Seattle Genetics’ stock triple in just five years. Dr. Clay Siegall is in it for the long-run, and he’s given cancer its final death-blow.

Leave a Reply

Your email address will not be published. Required fields are marked *